PortfoliosLab logo
WGS vs. OSCR
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between WGS and OSCR is 0.39, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.0
Correlation: 0.4

Performance

WGS vs. OSCR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in GeneDx Holdings Corp. (WGS) and Oscar Health, Inc. (OSCR). The values are adjusted to include any dividend payments, if applicable.

-90.00%-80.00%-70.00%-60.00%-50.00%December2025FebruaryMarchAprilMay
-88.80%
-62.07%
WGS
OSCR

Key characteristics

Sharpe Ratio

WGS:

2.54

OSCR:

-0.35

Sortino Ratio

WGS:

3.12

OSCR:

-0.09

Omega Ratio

WGS:

1.43

OSCR:

0.99

Calmar Ratio

WGS:

3.01

OSCR:

-0.35

Martin Ratio

WGS:

22.13

OSCR:

-0.77

Ulcer Index

WGS:

13.28%

OSCR:

30.98%

Daily Std Dev

WGS:

113.63%

OSCR:

68.85%

Max Drawdown

WGS:

-99.85%

OSCR:

-94.15%

Current Drawdown

WGS:

-92.11%

OSCR:

-64.10%

Fundamentals

Market Cap

WGS:

$1.78B

OSCR:

$3.32B

EPS

WGS:

-$1.39

OSCR:

$0.10

PS Ratio

WGS:

10.51

OSCR:

0.36

PB Ratio

WGS:

13.09

OSCR:

3.28

Total Revenue (TTM)

WGS:

$330.14M

OSCR:

$7.04B

Gross Profit (TTM)

WGS:

$211.05M

OSCR:

$7.04B

EBITDA (TTM)

WGS:

-$20.55M

OSCR:

-$103.09M

Returns By Period

In the year-to-date period, WGS achieves a -12.53% return, which is significantly lower than OSCR's -1.79% return.


WGS

YTD

-12.53%

1M

-20.78%

6M

-13.52%

1Y

244.77%

5Y*

N/A

10Y*

N/A

OSCR

YTD

-1.79%

1M

-1.27%

6M

-25.21%

1Y

-27.03%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

WGS vs. OSCR — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

WGS
The Risk-Adjusted Performance Rank of WGS is 9797
Overall Rank
The Sharpe Ratio Rank of WGS is 9898
Sharpe Ratio Rank
The Sortino Ratio Rank of WGS is 9595
Sortino Ratio Rank
The Omega Ratio Rank of WGS is 9494
Omega Ratio Rank
The Calmar Ratio Rank of WGS is 9797
Calmar Ratio Rank
The Martin Ratio Rank of WGS is 9999
Martin Ratio Rank

OSCR
The Risk-Adjusted Performance Rank of OSCR is 3333
Overall Rank
The Sharpe Ratio Rank of OSCR is 3333
Sharpe Ratio Rank
The Sortino Ratio Rank of OSCR is 3434
Sortino Ratio Rank
The Omega Ratio Rank of OSCR is 3434
Omega Ratio Rank
The Calmar Ratio Rank of OSCR is 2929
Calmar Ratio Rank
The Martin Ratio Rank of OSCR is 3535
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

WGS vs. OSCR - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for GeneDx Holdings Corp. (WGS) and Oscar Health, Inc. (OSCR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The chart of Sharpe ratio for WGS, currently valued at 2.54, compared to the broader market-2.00-1.000.001.002.003.00
WGS: 2.54
OSCR: -0.35
The chart of Sortino ratio for WGS, currently valued at 3.12, compared to the broader market-6.00-4.00-2.000.002.004.00
WGS: 3.12
OSCR: -0.09
The chart of Omega ratio for WGS, currently valued at 1.43, compared to the broader market0.501.001.502.00
WGS: 1.43
OSCR: 0.99
The chart of Calmar ratio for WGS, currently valued at 3.04, compared to the broader market0.001.002.003.004.005.00
WGS: 3.04
OSCR: -0.35
The chart of Martin ratio for WGS, currently valued at 22.13, compared to the broader market-40.00-30.00-20.00-10.000.0010.0020.00
WGS: 22.13
OSCR: -0.77

The current WGS Sharpe Ratio is 2.54, which is higher than the OSCR Sharpe Ratio of -0.35. The chart below compares the historical Sharpe Ratios of WGS and OSCR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.0010.0020.0030.0040.0050.00December2025FebruaryMarchAprilMay
2.54
-0.35
WGS
OSCR

Dividends

WGS vs. OSCR - Dividend Comparison

Neither WGS nor OSCR has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

WGS vs. OSCR - Drawdown Comparison

The maximum WGS drawdown since its inception was -99.85%, which is greater than OSCR's maximum drawdown of -94.15%. Use the drawdown chart below to compare losses from any high point for WGS and OSCR. For additional features, visit the drawdowns tool.


-90.00%-80.00%-70.00%-60.00%-50.00%December2025FebruaryMarchAprilMay
-88.80%
-64.10%
WGS
OSCR

Volatility

WGS vs. OSCR - Volatility Comparison

GeneDx Holdings Corp. (WGS) has a higher volatility of 62.23% compared to Oscar Health, Inc. (OSCR) at 14.56%. This indicates that WGS's price experiences larger fluctuations and is considered to be riskier than OSCR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%60.00%December2025FebruaryMarchAprilMay
62.23%
14.56%
WGS
OSCR

Financials

WGS vs. OSCR - Financials Comparison

This section allows you to compare key financial metrics between GeneDx Holdings Corp. and Oscar Health, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00500.00M1.00B1.50B2.00B2.50BJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025
87.12M
2.39B
(WGS) Total Revenue
(OSCR) Total Revenue
Values in USD except per share items

WGS vs. OSCR - Profitability Comparison

The chart below illustrates the profitability comparison between GeneDx Holdings Corp. and Oscar Health, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

-100.0%-50.0%0.0%50.0%100.0%JulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025
67.1%
100.0%
(WGS) Gross Margin
(OSCR) Gross Margin
WGS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, GeneDx Holdings Corp. reported a gross profit of 58.48M and revenue of 87.12M. Therefore, the gross margin over that period was 67.1%.
OSCR - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Oscar Health, Inc. reported a gross profit of 2.39B and revenue of 2.39B. Therefore, the gross margin over that period was 100.0%.
WGS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, GeneDx Holdings Corp. reported an operating income of -4.55M and revenue of 87.12M, resulting in an operating margin of -5.2%.
OSCR - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Oscar Health, Inc. reported an operating income of -147.73M and revenue of 2.39B, resulting in an operating margin of -6.2%.
WGS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, GeneDx Holdings Corp. reported a net income of -6.53M and revenue of 87.12M, resulting in a net margin of -7.5%.
OSCR - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Oscar Health, Inc. reported a net income of -153.55M and revenue of 2.39B, resulting in a net margin of -6.4%.